Eli Lilly & Co.
LLYStock
$1169.17+49.87%52W
Market Cap$1.09T
P/E52.75x
Div yield0.60%
Beta0.50
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-5.08%
Price vs S&P 500 (4W)2.44%
VGM Score55.47
Market Capitalization$1.09T
P/E Ratio (Annual)52.75x
Indicated Dividend Yield (Annual)0.60%
Earnings Surprise History
Q1 268.55est. 6.73
Analyst Recommendations
Mar 2026
Apr 2026
May 2026
Jun 2026
4.08
4.05
4.03
4.05
Industry Peers — Pharmaceuticals(563)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
LLYEli Lilly & Co. | D | B | B | $1169.17 |
| JNJJohnson & Johnson | D | C | B | $249.97 |
| ABBVABBVIE INC. | D | C | B | $254.39 |
| MRKMerck & Co., Inc. | C | C | B | $127.63 |
| NVSNovartis AG | C | C | C | $152.73 |
| NVONovo-Nordisk A/S | C | B | C | $51.48 |
| AZNAstraZeneca PLC | C | B | C | $169.29 |
| ABTAbbott Laboratories | C | C | D | $98.83 |
| PFEPfizer Inc. | B | C | C | $25.14 |
| VRTXVertex Pharmaceuticals Inc | D | C | C | $486.03 |
| BMYBristol-Myers Squibb Co. | B | C | B | $60.51 |
About
Eli Lilly is a pharmaceutical company with leading therapeutic portfolios in neuroscience, cardiometabolic disease, cancer, and immunology. The company's key franchises include blockbuster diabetes and obesity treatments (Mounjaro, Zepbound, Jardiance, Trulicity), foundational insulin products (Humalog, Humulin), the cancer therapy Verzenio, and immunology treatments (Taltz, Olumiant).